LAPALIEVA contains Lapatinib, an oral targeted anticancer agent. It is a tyrosine kinase inhibitor (TKI) that blocks HER2/neu (ErbB2) and EGFR (ErbB1) receptors, inhibiting tumor cell growth and proliferation in HER2-positive breast cancer.

Lapatinib is used for:

1. HER2-positive metastatic breast cancer – in combination with capecitabine after prior therapy

2. Advanced or metastatic breast cancer – in combination with letrozole in postmenopausal women with hormone receptor-positive tumors

3. Other HER2-positive tumors – in selected clinical trials

Common side effects:

• Diarrhea

•  Rash

•  Nausea and vomiting

•  Fatigue

•  Loss of appetite

Serious side effects:

•  Liver toxicity (elevated liver enzymes)

•  Heart function abnormalities (reduced LVEF)

•  Severe diarrhea leading to dehydration

•  Rare severe skin reactions

•  Standard dose: 1250 mg orally once daily (in combination with capecitabine)

•  Take 1 hour before or 1 hour after a meal

•  Dose adjustment may be required for hepatic impairment or side effects


NOTE: This medicine should be taken only under a doctor’s supervision.